Sean Maduck's SEC Form 4 filings reveal a persistent sell-side bias concentrated entirely in Corcept Therapeutics (CORT). Across 52 transactions spanning roughly eight months, Maduck executed no open-market purchases, while selling approximately $19.1 million worth of shares. The most recent activity, clustered in late May through early July 2026, shows nine open-market sales totaling roughly $8.9 million, including a $3.57 million disposition on May 27 and a combined $2.21 million across three separate sales on July 1. These sales were consistently paired with option exercises (coded M) at $206,750 to $620,250, suggesting the shares sold were largely sourced from exercised options rather than accumulated holdings.
The pattern is one of systematic monetization rather than opportunistic timing. Maduck’s sales occurred at regular intervals—November, December, March, May, June, and July—with each tranche preceded by an option exercise of identical value ($165,400 in November and December, $206,750 in June and July, and $620,250 in May). The only non-sale transactions were routine compensation events: restricted stock grants (coded A) totaling roughly $92,280 across four awards, and small tax-withholding dispositions (coded F) of $3,956 to $31,838. Two zero-value gifts in January 2026 further confirm that Maduck’s activity is driven by liquidity needs or portfolio rebalancing, not a directional bet on CORT’s prospects.
Notably, Maduck’s selling has accelerated in recent months. The May 27 sale alone ($4.92 million combined with the option exercise) exceeded the total value of all sales in the prior six months combined. This trajectory, coupled with the complete absence of buy-side conviction signals, paints a clear picture: Maduck is a consistent net seller of CORT stock, with no recent indication of accumulation or a shift toward a more bullish stance.
AI-assisted summary